Dianthus Therapeutics vs Upstream Bio
DNTH and UPB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DNTH and UPB compare
Dianthus Therapeutics is the larger company, worth 25 times as much as Upstream Bio ($4.6B against $187M).
Upstream Bio scores higher on the StockData Score (9 against 7 for Dianthus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DNTH | UPB |
|---|---|---|
| Size and price | ||
| Market cap | $4.6B | $187M |
| Share price | $82.38 | $3.41 |
| Change, 1 year | 144% | −85.9% |
| Change, 5 years | −34.5% | – |
| Beta (5Y) | 1.47 | 1.47 |
| Employees | 92 | 75 |
| StockData Score | ||
| Total score | 7 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 59.1× |
| P/B | 3.9× | 0.7× (better) |
| Growth | ||
| Revenue growth (TTM) | – | 16.0% |
| Profitability | ||
| Operating margin | – | −5383% |
| Net margin | – | −4956% |
| Return on equity | −26.1% (better) | −46.0% |
| Return on invested capital | −25.4% (better) | −1082% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 26.10 | 27.99 (better) |
| Altman Z-score | 66.80 (better) | 8.07 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | −0.01% | – |
| Shareholder yield | −0.01% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 118% | 92.3% |
| Held by insiders | 9.1% | 8.6% |
| Insider net buying, 12 months | −$71.2M | −$105K (better) |
| Short interest, % of float | 18.0% | 9.0% |
Go deeper
- DNTH stock overview
- DNTH income statement
- DNTH valuation and score
- UPB stock overview
- UPB income statement
- UPB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.